$4 CA COMPANY HAS ORPHAN DRUG STATUS FOR UVEITIS CUREMONEY MAP PRESS, is touting a small drug company with ”190 years of experience” and former FDA lawyer on the Board of directors”…Lots of hype about astronomical profits from this ”interleukin inhibitor”…
can we figure out the company and it’s symbol?
A Uveitis cure would be a great breakthrough, and considered ”cheap” at $21000/year…would it be necessary to use it for life, or is the ”cure” permanent after treatment? Please ask DR K about it.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
XOMA-Please read Stockgumshoe comments prior to buyng this stock and do your DD
Have perpetually awesome days-Ben
buyer beware this stock losing not gaining!!!!!
dislike!
Notice that several drug companies also received orphan drug status for treatments/drugs for uveitis and with diversified product lines. Check out ABBV’s story.
My wife is totally blind in her right eye and almost all of her let one. If anyone knows the name of the manufacturer of the product in question please advise.
Energy advisor has the name but it will cost you almost 1,900.00 but also land you ,4$ share! If you find out please let me know ! Kellybeilfuss@yahoo.com note to me uveitis cure stock name thanks
Kelly, They claim it is XOMA, XOMA, Inc.I I wish it were true but I really don’t know. I’m hoping Stock Gumshoe can shed some light on it soon.
Kelly please let me know if you find out what the Stock is or Stock symbol if you find out for this…thanks much… Kevin
It’s a company in California called Xoma. http://Www.xoma.com. Good luck.
cost is 1900 to get info; I’m still researching and see the name Santan and Ligan–do not know for sure; please let all of us know as I will if the name is discovered.
It is XOMA, it has been posted here for three weeks now.
I purchased the 1900 membership 2 weeks ago and it is in fact XOMA. The stock has risen and lowered since then.
Thanks for sharing information that you paid a lot of money for to get.
Are you happy with the service you get considering the hight cost of membership?
Is that newsletter for $1999 have any truly great info that it would be worth that price?
We might do better doing our own research than getting all the teasers they like to throw out there. And it requires you subscribe to another newletter.This one $1900 .I am fed up with Money Map and all their advertisements for other companies. Every newsletter I try is just about trying to sell you more crap from an affiliate.
You are RIGHT ON… If these stock “wizards” are so bright, why do they need our money? All they want to do is sell is more of their multiple services…. BUT I do keep looking 🙁
XOMA is a well run company with a very promising self injectable biologic drug employing a novel mechanism of action. Uveitis is a leading cause of blindness and visual disability, especially because it strikes young people. Most uveitis patients would use Xoma’s gevokizumab for many years at least, but lifelong administration remains hypothetical at this point. The safety profile appears to be acceptable as well. However, there will be considerable competition, particularly from pharmaceutical giant Abbvie, which has data strongly supporting the efficacy of its already approved biologic drug Humira (adalimumab) for its next indication: uveitis. Furthermore, the last 2 drug approvals for uveitis were for depot steroids placed directly into the eye, Retisert (Bausch & Lomb) and Ozudex (Allergan), neither of which seem to be making much money for either company. Finally, FDA approval does not equal insurance carrier approval, which may delay full implementation of any new “orphan” medication by years.
Well I’ve had Abbvie stock for a long time and they are winner. I did buy some XOMA, but if I get advise from Stock Gumshoe, I’ll sell it in a heartbeat !
let me know if xoma is a good buy
Just wondering John Boudreaux if the stock you bought from XOMA has changed in value since your purchase.
Here is a link to the clinical trial study for the Xoma drug Gevokizumab developed for the treatment of Behcet’s Disease Uveitis. The drug does have Orphan status. The study is expected to be completed by November 2015.
https://www.clinicaltrials.gov/ct2/show/NCT02258867?term=A+RandomizEd-Withdrawal%2C+Double-Masked%2C+Placebo-Controlled+StudY+of+the+Efficacy+and+Safety+of+GevokizUmAb+in+TReating+Subjects+with+Beh%C3%A7et%27s+Disease+UveitiS&rank=1
I talked to the Uveitis foundation(I think) and they wondered why they were getting all the calls all of a sudden. I told them it was pitched by a newsletter. She indicated that the price mentioned must be Xoma but she added they were no further along than a number of other companies who were much larger and couldn’t understand all the fuss. I get several newsletter from the same group pitching this and I can tell you they all just keep pounding away on this stock and it is lower than when all this started. I wondered how much stock they much have bought frontrunning this thing. I will bet I have had 20 plus teases on this. Makes me very suspicious.
It is the hustlers at MoneyMap Press. The do a pitch that causes an attack of extreme greed w/o giving info so you will fork over dough for access to worthless info …. FRAUD ALERT
Sounds like a Pump-n-Dump to me. I too am getting several emails a day touting this $4/share, $28M in sales, orphan drug company. My initial research took me to PSDV, pSivida, a $4.06/share, also $28M in sales, company with a phaseIII Uveitis drug Medidur. Comparing the two, XOMA’s number look terrible (not unheard of for biopharms). AND, I simply do NOT see the touted 90% insider buying MMPress is talking about – quite the opposite (-90.33% SELLING from NOV14 through JAN15)
Looking at PSDV, it ACTUALLY looks like a great company – great numbers, tons of cash, good margins. What do they do? Nano, bioedible, injectionable delivery vehicles for treatment up to 36 months. Also, they continually receive marketing licenses worldwide.
Could XOMA do the “pump” soon? Sure, but obviously takes a huge email campaign to make that happen…classic!
I saw a pump-n-dump email campaign like this a few years ago with a Canadian lithium mining company where shares started around $1/share and projected to go over $10/share. It did just that and then fell flat at under $1/share within 2 weeks. If you can get in around $4/share and sell 20% when/if it reaches $20/share you will make your money back then you could let the rest ride and see if it is a hit. Or, you could sell all at $20/share (or whatever margin you set) and run with a four fold profit. I smell pump-n-dump all over this one. Trick with those is getting out before the down turn!
Another company with the designation ‘orphan’ is TXCELL SA…
Like Evin, I also stumbled on Psivida. It looks good to me. It’s products are used for uveitis plus other conditions. Bloomberg has an estimated PE of 14.1. Scheduled to report earnings 02/06. I’m watching it.
Does anybody know what’s up with XOMA?
Did it pass Phase 3 trials at the end of the year?
I got a new letter about his one again today. Well, did the Gumshoe ever post an analysis about this one?
Me too. What’s the score? I mean is it pump-n-dump or the real thng?
Has anyone heard anything on Ekso Bionics? This one has apparently blown-up in their face. It was heavily touted. Don’t see much on it anymore. Let me rephrase that. I haven’t seen anything on it.